CN112714769A - Ror-1特异性嵌合抗原受体及其用途 - Google Patents

Ror-1特异性嵌合抗原受体及其用途 Download PDF

Info

Publication number
CN112714769A
CN112714769A CN201980059126.7A CN201980059126A CN112714769A CN 112714769 A CN112714769 A CN 112714769A CN 201980059126 A CN201980059126 A CN 201980059126A CN 112714769 A CN112714769 A CN 112714769A
Authority
CN
China
Prior art keywords
polypeptide
cell
cells
seq
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980059126.7A
Other languages
English (en)
Chinese (zh)
Inventor
鲁图尔·R·沙阿
陈昶宏
谢丽尔·G·博林格
维诺德哈布·库雷拉
艾米·维萨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Presagern Co
Original Assignee
Presagern Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Presagern Co filed Critical Presagern Co
Publication of CN112714769A publication Critical patent/CN112714769A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201980059126.7A 2018-07-10 2019-07-10 Ror-1特异性嵌合抗原受体及其用途 Pending CN112714769A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862696075P 2018-07-10 2018-07-10
US62/696,075 2018-07-10
PCT/US2019/041213 WO2020014366A1 (en) 2018-07-10 2019-07-10 Ror-1 specific chimeric antigen receptors and uses thereof

Publications (1)

Publication Number Publication Date
CN112714769A true CN112714769A (zh) 2021-04-27

Family

ID=69141807

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980059126.7A Pending CN112714769A (zh) 2018-07-10 2019-07-10 Ror-1特异性嵌合抗原受体及其用途

Country Status (11)

Country Link
US (1) US12275772B2 (enExample)
EP (1) EP3820484A4 (enExample)
JP (2) JP2021530217A (enExample)
KR (1) KR20210043562A (enExample)
CN (1) CN112714769A (enExample)
AU (1) AU2019301147A1 (enExample)
CA (1) CA3105816A1 (enExample)
IL (1) IL280029A (enExample)
SG (1) SG11202100205UA (enExample)
WO (1) WO2020014366A1 (enExample)
ZA (1) ZA202100391B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116284246A (zh) * 2022-12-12 2023-06-23 江苏三联生物工程股份有限公司 信号肽、核酸片段、重组表达载体、宿主细胞及其应用
CN119233991A (zh) * 2022-05-24 2024-12-31 卡里布生物科学公司 抗ror1抗体和ror1靶向性经工程化的细胞

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
JP2021500882A (ja) * 2017-10-18 2021-01-14 プレシゲン，インコーポレイテッド スペーサーを含むポリペプチド組成物
AU2019301147A1 (en) 2018-07-10 2021-01-21 Precigen, Inc. ROR-1 specific chimeric antigen receptors and uses thereof
JP7632868B2 (ja) * 2018-10-26 2025-02-19 国立大学法人信州大学 高効率な遺伝子改変細胞の作製方法
EP4028413A1 (en) 2019-09-10 2022-07-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
WO2021189008A1 (en) 2020-03-20 2021-09-23 Lyell Immunopharma, Inc. Novel recombinant cell surface markers
WO2021191870A1 (en) 2020-03-27 2021-09-30 Dcprime B.V. Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy
CN113584083A (zh) * 2020-04-30 2021-11-02 深圳市深研生物科技有限公司 用于逆转录病毒载体的生产细胞和包装细胞及其制备方法
EP4171617A1 (en) 2020-06-30 2023-05-03 Mendus B.V. Use of leukemia-derived cells in ovarian cancer vaccines
EP4240405A1 (en) 2020-11-05 2023-09-13 Mendus B.V. Use of tumor-independent antigens in immunotherapies
WO2022143928A1 (zh) * 2020-12-31 2022-07-07 亘喜生物科技（上海）有限公司 膜融合蛋白及其在免疫细胞中的应用
CA3204211A1 (en) * 2021-01-11 2022-07-14 Helen SABZEVARI Chimeric receptor therapy
KR20230135075A (ko) 2021-01-22 2023-09-22 멘두스 비.브이. 종양 백신접종 방법
AU2022212307A1 (en) * 2021-02-01 2023-08-17 The Regents Of The University Of California Treatment of neuroendocrine cancers
WO2022182891A1 (en) 2021-02-25 2022-09-01 Lyell Immunopharma, Inc. Ror1 targeting chimeric antigen receptor
JP2024508597A (ja) * 2021-03-09 2024-02-28 四川科倫博泰生物医薬股▲フン▼有限公司 Ｒｏｒ１結合タンパク質及びその用途
IL310901A (en) * 2021-08-18 2024-04-01 Univ Pennsylvania Compositions and methods for chimeric antigen receptors specific to b cell receptors
JP2024540099A (ja) 2021-10-28 2024-10-31 ライエル・イミュノファーマ・インコーポレイテッド Ｒｏｒ１結合タンパク質を発現する細胞を培養する方法
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN118206620A (zh) * 2022-12-09 2024-06-18 上海细胞治疗集团股份有限公司 一种多肽标签及其应用
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025194140A1 (en) * 2024-03-15 2025-09-18 Port Therapeutics, Inc. Thermally controlled gene expression and uses thereof
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106922148A (zh) * 2014-07-29 2017-07-04 瑟勒提斯公司 用于癌症免疫疗法的ror1(ntrkr1)特异性的嵌合抗原受体
CN107428833A (zh) * 2015-01-16 2017-12-01 朱诺治疗学股份有限公司 Ror1特异性抗体和嵌合抗原受体

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP0910652B1 (en) 1996-04-05 2014-10-08 The Salk Institute For Biological Studies Hormone-mediated methods for modulating expression of exogenous genes in mammalian systems, and products related thereto
CA2296093A1 (en) 1997-07-10 1999-01-21 The Salk Institute For Biological Studies Modified lepidopteran receptors and hybrid multifunctional proteins for use in regulation of transgene expression
US6333318B1 (en) 1998-05-14 2001-12-25 The Salk Institute For Biological Studies Formulations useful for modulating expression of exogenous genes in mammalian systems, and products related thereto
WO2011159847A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
EP3828205A1 (en) * 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
WO2012097313A2 (en) * 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
WO2012122025A2 (en) * 2011-03-04 2012-09-13 Intrexon Corporation Vectors conditionally expressing protein
KR102086874B1 (ko) * 2012-04-11 2020-03-10 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 B-세포 성숙 항원을 표적화하는 키메라 항원 수용체
US10066019B2 (en) * 2012-10-12 2018-09-04 Agency For Science, Technology And Research Optimised heavy chain and light chain signal peptides for the production of recombinant antibody therapeutics
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP2997134B1 (en) 2013-05-14 2020-06-24 Board of Regents, The University of Texas System Human application of engineered chimeric antigen receptor (car) t-cells
US20160311879A1 (en) 2013-12-18 2016-10-27 Intrexon Corporation Single chain il-12 nucleic acids, polypeptides, and uses thereof
CA2956482A1 (en) * 2014-07-31 2016-02-04 Cellectis Ror1 specific multi-chain chimeric antigen receptor
EP3197911A4 (en) 2014-09-22 2018-06-20 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
JP2018521004A (ja) * 2015-05-18 2018-08-02 ユーリカ セラピューティックス， インコーポレイテッド 抗ｒｏｒ１キメラ抗原受容体
WO2017062953A1 (en) 2015-10-10 2017-04-13 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
EP4094780A3 (en) 2016-02-12 2023-02-08 University of Massachusetts Anti-angiogenic mirna therapeutics for inhibiting corneal neovascularization
AU2017244108B2 (en) * 2016-03-29 2021-03-18 University Of Southern California Chimeric antigen receptors targeting cancer
AU2017279548B2 (en) * 2016-06-08 2024-08-08 Precigen, Inc. CD33 specific chimeric antigen receptors
EP3548047A4 (en) * 2016-11-30 2020-07-01 Intrexon Corporation ADMINISTRATION OF STEROIDS AND IMMUNOTHERAPY
EP3551197B1 (en) * 2016-12-12 2023-11-22 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
SG11201906213UA (en) * 2017-01-10 2019-08-27 Intrexon Corp Modulating expression of polypeptides via new gene switch expression systems
US11118168B2 (en) 2017-06-07 2021-09-14 Precigen, Inc. Expression of novel cell tags
JP2021500882A (ja) 2017-10-18 2021-01-14 プレシゲン，インコーポレイテッド スペーサーを含むポリペプチド組成物
AU2019244479B2 (en) 2018-03-30 2024-12-19 Les Hopitaux Universitaires De Geneve Micro RNA expression constructs and uses thereof
AU2019301147A1 (en) 2018-07-10 2021-01-21 Precigen, Inc. ROR-1 specific chimeric antigen receptors and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106922148A (zh) * 2014-07-29 2017-07-04 瑟勒提斯公司 用于癌症免疫疗法的ror1(ntrkr1)特异性的嵌合抗原受体
CN107428833A (zh) * 2015-01-16 2017-12-01 朱诺治疗学股份有限公司 Ror1特异性抗体和嵌合抗原受体

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119233991A (zh) * 2022-05-24 2024-12-31 卡里布生物科学公司 抗ror1抗体和ror1靶向性经工程化的细胞
CN116284246A (zh) * 2022-12-12 2023-06-23 江苏三联生物工程股份有限公司 信号肽、核酸片段、重组表达载体、宿主细胞及其应用

Also Published As

Publication number Publication date
SG11202100205UA (en) 2021-02-25
ZA202100391B (en) 2025-05-28
CA3105816A1 (en) 2020-01-16
JP2024073449A (ja) 2024-05-29
KR20210043562A (ko) 2021-04-21
EP3820484A1 (en) 2021-05-19
IL280029A (en) 2021-03-01
AU2019301147A1 (en) 2021-01-21
EP3820484A4 (en) 2022-05-04
JP2021530217A (ja) 2021-11-11
US12275772B2 (en) 2025-04-15
US20210177902A1 (en) 2021-06-17
WO2020014366A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
CN112714769A (zh) Ror-1特异性嵌合抗原受体及其用途
AU2018207281B2 (en) Modulating expression of polypeptides via new gene switch expression systems
AU2018281316B2 (en) Expression of novel cell tags
KR102652827B1 (ko) Cd33 특이적 키메라 항원 수용체
AU2018352984B2 (en) Polypeptide compositions comprising spacers
US11976134B2 (en) MUC16 specific chimeric antigen receptors and uses thereof
KR20230143140A (ko) 키메라 수용체 요법
WO2019118895A1 (en) Daric interleukin receptors
RU2795198C2 (ru) Специфичные к muc16 химерные антигенные рецепторы и их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: American Maryland

Applicant after: Presagern Co.

Address before: Virginia

Applicant before: Presagern Co.

Country or region before: U.S.A.